Clinical Trials Directory

Trials / Completed

CompletedNCT02379715

Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
26 (actual)
Sponsor
Ajou University School of Medicine · Academic / Other
Sex
All
Age
19 Years – 60 Years
Healthy volunteers
Accepted

Summary

Desflurane is a halogenated ether with low solubility, giving rapid induction and emergence from anesthesia This character is suitable for Volatile Induction and Maintenance Anesthesia (VIMA). But desflurane can cause airway irritation when it used as a sole induction agent to adult or children, so there were many studies about reducing the airway reflex combined with desflurane. Remifentanil is a short acting opioid and is quickly hydrolyzed by nonspecific esterase in the plasma and multiorgan. Several studies suggest the optimal dose of remifentanil for reducing airway reflex or cardiovascular response for intubation combined with desflurane. But these studies were under 1 Minimal Alveolar Concentration (MAC) of desflurane and this point could be a limitation because desflurane concentration over 1 MAC increase airway irritation significantly. This study this study was designed to determine a median effective effect-site concentration (EC50) of remifentanil to prevent airway irritation during desflurane anesthesia over 1 MAC.

Conditions

Interventions

TypeNameDescription
DRUGRemifentanil
DRUGDesflurane

Timeline

Start date
2014-12-01
Primary completion
2015-05-01
Completion
2015-05-01
First posted
2015-03-05
Last updated
2020-08-20

Source: ClinicalTrials.gov record NCT02379715. Inclusion in this directory is not an endorsement.